A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY

Official Summary

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.

Eligibility Requirements

• Minimum Age: 18 Years

Study Design

• Study Type: INTERVENTIONAL
• Allocation: RANDOMIZED
• Model: PARALLEL
• Masking: NONE
• Enrollment: 492 participants

Study Arms

• Elranatamab (EXPERIMENTAL)
  Participants will receive elranatamab monotherapy
• Investigator's Choice (ACTIVE_COMPARATOR)
  Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)

Interventions

• DRUG: Elranatamab — Elranatamab will be administered subcutaneously
• DRUG: Elotuzumab — Elotuzumab will be administered intravenously
• DRUG: Pomalidomide — Pomalidomide will be administered orally
• DRUG: Dexamethasone — Dexamethasone will be administered orally
• DRUG: Bortezomib — Bortezomib will be administered subcutaneously or intravenously

Primary Outcomes

• Progression free survival per International Myeloma Working Group criteria (Up to approximately 5 years)

Secondary Outcomes

• Overall survival (Up to approximately 5 years)
• Progression free survival on next-line treatment per International Myeloma Working Group criteria (Up to approximately 5 years)
• Objective response rate per International Myeloma Working Group criteria (Up to approximately 5 years)
• Duration of response per International Myeloma Working Group criteria (Up to approximately 5 years)
• Very good partial response or better response rate per International Myeloma Working Group criteria (Up to approximately 5 years)

Eligibility Criteria

Inclusion Criteria:

* Prior diagnosis of multiple myeloma as defined by International Myeloma Working Group (IMWG) criteria and previously received 1 to 4 prior lines of therapy including prior anti-cluster of differentiation 38 (CD38) antibody and prior lenalidomide.
* Documented evidence of progressive disease or failure to achieve a response to last line of therapy per IMWG criteria.
* Measurable disease defined as at least 1 of the following: (a) Serum M-protein ≥0.5 g/dL; (b) Urinary M-protein excretion ≥200 mg/24 hours; (c) Serum involved immunoglobulin FLC ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda FLC ratio (\<0.26 or \>1.65).
* Have clinical laboratory values within the specified range.
* ECOG (Eastern Cooperative Oncology Group) performance status ≤2.
* Not pregnant or breastfeeding and willing to use contraception.

Exclusion Criteria:

* Smoldering multiple myeloma.
* Plasma cell leukemia.
* Amyloidosis.
* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin abnormalities (POEMS) syndrome.
* Known central nervous system (CNS) involvement or clinical signs of myelomatous meningeal involvement.
* Stem cell transplant within 12 weeks prior to enrolment, or active graft versus host disease.
* Any active, uncontrolled bacterial, fungal, or viral infection.
* Any other active malignancy within 3 years prior to enrolment (exceptions include, adequately treated basal cell or squamous cell skin cancer, carcinoma in situ)
* Previous treatment with a B cell maturation antigen (BCMA)-directed therapy or CD3-redirecting therapy.
* Unable to receive investigator's choice therapy.
* Live attenuated vaccine within 4 weeks of the first dose of study intervention.
* Administration with an investigational product (e.g. drug or vaccine) within 30 days preceding the first dose of study intervention used in this study.

Trial Locations

• Infirmary Cancer Care, Mobile, Alabama, United States
• Western Regional Medical Center, Inc. dba. City of Hope Phoenix, Goodyear, Arizona, United States
• Beverly Hills Cancer Center, Beverly Hills, California, United States
• Clovis Community Medical Center, Clovis, California, United States
• Community Cancer Institute, Clovis, California, United States
• Clinical Research Advisors (Encino Satellite Location), Encino, California, United States
• University of California San Francisco, Fresno, California, United States
• Community Regional Medical Center, Fresno, California, United States
• Hoag Health Center Irvine, Irvine, California, United States
• Hoag Hospital Irvine, Irvine, California, United States
• ...and 10 more locations

Contact Information

• Pfizer CT.gov Call Center — CONTACT
  Phone: 1-800-718-1021
  Email: ClinicalTrials.gov_Inquiries@pfizer.com

Study Officials

• Pfizer CT.gov Call Center — STUDY_DIRECTOR
  Pfizer

More Multiple Myeloma Trials

View all Multiple Myeloma clinical trials